TuHURA Biosciences, Inc./NV 10-Q

Item 4. Controls and Procedures. Disclosure Controls and Procedures Management, with the participation of the Chief Executive Officer and Chief Financial Officer, conducted an evaluation (as required by Rule 13a-15 under the Exchange Act) of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective as of the end of the period covered by this report, due to the material weakness in internal control over financial reporting as discussed in the Company’s Annual Report on Form 10-K for the year ended June 30, 2020, filed with the SEC on September 18, 2020. Changes in internal controls There have been no changes in our internal control over financial reporting that occurred during the quarter ended March 31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. 46 PART II - OTHER INFORMATION Item 1. Legal Proceedings. There are no legal proceedings the Company is party to or any of its property is subject to. Item 1A. Risk Factors. None.